ebook Munafa Stock Market Course + Intraday & FNO calls  

       

NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

Novo Nordisk A/s Complete list of announcements declared & dividend announcements by Novo Nordisk A/s NVO

Novo Nordisk A/s NVO listed on NYSE and deals in Health Care Major Pharmaceuticals

Announcements and dividends declared by Novo Nordisk A/s NVO

India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make semaglutide
The order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape competitive dynamics in a market valued at around Rs 850 crore.
Announcement as on 03 December 2025

Generic drug companies rework pricing to gain weight in India’s GLP-1 market as Novo Nordisk slashes Wegovy prices
Indian drugmakers are adjusting prices for weight-loss injections after Novo Nordisk cut prices for its drug Wegovy. This move is prompting generic companies to lower their expected launch prices. Novo Nordisk is also preparing to launch Ozempic in India s
Announcement as on 26 November 2025

Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study
Novo Nordisk said its new experimental obesity drug, amycretin, delivered up to 14.5% weight loss at 36 weeks in type 2 diabetes patients in a mid-stage trial. The drug was found to be safe with mostly mild gastrointestinal side effects, and the company pl
Announcement as on 25 November 2025

Novo Nordisk India prioritises patient outcomes; revenue growth follows naturally, says Shrotriya
Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The company is preparing for semaglutide patent expiry next year by focusing on trust, quality, and education, mirroring
Announcement as on 19 November 2025

Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India
Eli Lilly and Novo Nordisk leaders share their India strategies for weight-loss drugs. They focus on pricing, market expansion and countering generics after semaglutide's patent ends. Both companies aim to increase patient access to their innovative thera
Announcement as on 18 November 2025

Announcements by Novo Nordisk A/s first page | Next page | Prev page |

NVO Novo Nordisk A/s current price & indicator signals

Moving Averages for Novo Nordisk A/s

  • 5Day Average: 46.27
  • 12Day Average: 46.57
  • 20Day Average: 46.49
  • 50Day Average: 47.9
  • 100Day Average: 45.9
  • 150Day Average: 44.11
  • 200Day Average: 46.4

NVO Indicators & signals

Indicator MACD (12,26,9)

46.53, 46.78, -0.35
Indicator MACD is in negative zone

Indicator ADX (14)

4.23, 24.83, 22.82
Indicator ADX is indicating that momentum is weak.
Indicator ADX is showing that momentum is towards buying

Indicator RSI (14)

Current RSI is: 50
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of NVO Novo Nordisk A/s are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
04 Fri Sep 2026 46.63 46.04 to 47.45 -1.85% 0.44 times
03 Thu Sep 2026 47.51 46.57 to 48.00 1.6% 0.86 times
02 Wed Sep 2026 46.76 45.17 to 47.01 3.63% 0.9 times
01 Tue Sep 2026 45.12 45.07 to 46.16 -0.46% 0.92 times
31 Mon Aug 2026 45.33 44.95 to 45.61 -0.61% 0.75 times
28 Fri Aug 2026 45.61 45.41 to 46.21 -1.41% 0.84 times
27 Thu Aug 2026 46.26 45.70 to 46.33 -1.97% 1.28 times
26 Wed Aug 2026 47.19 46.87 to 48.04 -3.02% 0.88 times
25 Tue Aug 2026 48.66 47.56 to 48.66 3.71% 1.53 times
24 Mon Aug 2026 46.92 46.57 to 47.30 0.39% 0.95 times
21 Fri Aug 2026 46.74 46.34 to 47.17 1.3% 1.08 times
20 Thu Aug 2026 46.14 46.11 to 46.90 -0.71% 0.95 times

Videos related to: NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

Hindi Video Most Important Stock Market Video. No Success Without This Formula

Hindi Video What Is Needed To Succeed In Stock Markets

NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

 

Back to top